Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


Articles published in Int J Urol

Retrieve available abstracts of 149 articles:
HTML format



Single Articles


    February 2024
  1. PARK SJ, Park YJ, Park SM
    Response to comment: Revisiting the impact of antibiotics on prostate cancer risk: Beyond the gut microbiota.
    Int J Urol. 2024 Feb 15. doi: 10.1111/iju.15431.
    PubMed    


  2. OBINATA D, Takayama K, Inoue S, Takahashi S, et al
    Exploring androgen receptor signaling pathway in prostate cancer: A path to new discoveries.
    Int J Urol. 2024 Feb 12. doi: 10.1111/iju.15424.
    PubMed     Abstract available


  3. ASAI S, Kobayashi M, Fukuda S, Kimura K, et al
    Significance of atypical nodules upgraded to category 3 in Prostate Imaging Reporting and Data System version 2.1 for prostate cancer diagnosis.
    Int J Urol. 2024 Feb 12. doi: 10.1111/iju.15421.
    PubMed    


  4. HIYAMA Y
    Editorial Comment: Proctoscopy following transrectal prostate biopsy can control rectal bleeding after prostate biopsy.
    Int J Urol. 2024;31:143.
    PubMed    


    January 2024
  5. SHOJI S
    Editorial Comment to Histological parameters and stromal desmoplastic status affecting accurate diagnosis of extraprostatic extension of prostate cancer using multi-parametric magnetic resonance imaging.
    Int J Urol. 2024 Jan 29. doi: 10.1111/iju.15406.
    PubMed    


  6. LIN YH, Chen YT, Tsai HY
    Revisiting the impact of antibiotics on prostate cancer risk: Beyond the gut microbiota.
    Int J Urol. 2024 Jan 29. doi: 10.1111/iju.15401.
    PubMed    


  7. MORI K
    Editorial Comment from Dr Mori to Association between antibiotic use and subsequent risk of prostate cancer: A retrospective cohort study in South Korea.
    Int J Urol. 2024 Jan 24. doi: 10.1111/iju.15402.
    PubMed    


  8. HATANO K
    Editorial Comment on "Association between antibiotic use and subsequent risk of prostate cancer: A retrospective cohort study in South Korea".
    Int J Urol. 2024 Jan 12. doi: 10.1111/iju.15393.
    PubMed    


  9. UKIMURA O
    Editorial Comment on Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
    Int J Urol. 2024 Jan 10. doi: 10.1111/iju.15392.
    PubMed    


  10. TSUKUDA F, Tanaka Y, Narita S, Shimizu T, et al
    Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
    Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15373.
    PubMed     Abstract available


  11. OKIHARA K, Ueda T, Fujihara A, Shiraishi T, et al
    Novel image-guided marker aimed at organ-preserving therapies for prostate cancer.
    Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15389.
    PubMed     Abstract available


  12. OKANO K, Miyai K, Mikoshi A, Edo H, et al
    Histological parameters and stromal desmoplastic status affecting accurate diagnosis of extraprostatic extension of prostate cancer using multi-parametric magnetic resonance imaging.
    Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15385.
    PubMed     Abstract available


  13. DE VELASCO MA, Kura Y, Fujita K, Uemura H, et al
    Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer.
    Int J Urol. 2024 Jan 2. doi: 10.1111/iju.15378.
    PubMed     Abstract available


  14. NAITO Y, Kato M, Nagayama J, Sano Y, et al
    Recent insights on the clinical, pathological, and molecular features of intraductal carcinoma of the prostate.
    Int J Urol. 2024;31:7-16.
    PubMed     Abstract available


    December 2023
  15. YOKOMIZO A, Shiota M, Morokuma F, Eto M, et al
    GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401.
    Int J Urol. 2023 Dec 26. doi: 10.1111/iju.15371.
    PubMed     Abstract available


  16. PARK SJ, Hong J, Park YJ, Jeong S, et al
    Association between antibiotic use and subsequent risk of prostate cancer: A retrospective cohort study in South Korea.
    Int J Urol. 2023 Dec 21. doi: 10.1111/iju.15364.
    PubMed     Abstract available


  17. NAKAZONO M, Urabe F, Iwatani K, Imai Y, et al
    Patients with PSA below 0.2 ng/mL at 8 years post high-dose-rate brachytherapy have an extremely low risk of subsequent recurrence.
    Int J Urol. 2023;30:1147-1154.
    PubMed     Abstract available


    November 2023
  18. YUASA T
    Editorial Comment to Bone-modifying agents are protective for symptomatic skeletal events in radium-223 treatment.
    Int J Urol. 2023;30:1034-1035.
    PubMed    


  19. SHIRAISHI K
    Evaluation of sexual function after robot-assisted radical prostatectomy: A farewell to IIEF questionnaire.
    Int J Urol. 2023;30:959-967.
    PubMed     Abstract available


  20. BLAS L, Shiota M, Matsumoto T, Hori Y, et al
    Bone-modifying agents are protective for symptomatic skeletal events in Radium-223 treatment.
    Int J Urol. 2023;30:1029-1034.
    PubMed     Abstract available


  21. KOHADA Y, Hieda K, Miyamoto S, Tasaka R, et al
    Retrospective evaluation of the improvement in the urinary status-related quality of life after robot-assisted radical prostatectomy.
    Int J Urol. 2023;30:1020-1027.
    PubMed     Abstract available


    August 2023
  22. MATSUOKA Y, Ueno Y, Uehara S, Tanaka H, et al
    Deep-learning prostate cancer detection and segmentation on biparametric versus multiparametric magnetic resonance imaging: Added value of dynamic contrast-enhanced imaging.
    Int J Urol. 2023 Aug 22. doi: 10.1111/iju.15280.
    PubMed     Abstract available


  23. INOUE T, Shin T
    Current magnetic resonance imaging-based diagnostic strategies for prostate cancer.
    Int J Urol. 2023 Aug 17. doi: 10.1111/iju.15281.
    PubMed     Abstract available


  24. SHIOTA M, Terada N, Kimura T, Kitamura H, et al
    Differential cancer-specific survival with curative radiotherapy to the prostate for metastatic prostate cancer according to estimated survival by risk group.
    Int J Urol. 2023 Aug 10. doi: 10.1111/iju.15273.
    PubMed    


    July 2023
  25. YASUDA Y, Sakurai M, Numao N, Yamamoto S, et al
    Efficacy and safety profile of olaparib for patients with metastatic castration-resistant prostate cancer: A preliminary report of real-world data in a single institution in Japan.
    Int J Urol. 2023 Jul 26. doi: 10.1111/iju.15261.
    PubMed    


  26. YANG X, Tan YG, Gatsinga R, Chen W, et al
    Far from the truth: Real-world treatment patterns among newly diagnosed metastatic prostate cancer in the era of treatment intensification.
    Int J Urol. 2023 Jul 11. doi: 10.1111/iju.15243.
    PubMed     Abstract available


  27. TANAKA R, Hatakeyama S, Narita S, Sakurai T, et al
    Trends in the use of local intervention for metastatic hormone-naive prostate cancer: A multicenter retrospective study.
    Int J Urol. 2023 Jul 5. doi: 10.1111/iju.15240.
    PubMed     Abstract available


  28. ISHII N, Hatakeyama S, Miura H, Tanaka R, et al
    Trends in the age of hospitalized patients with urological cancers: A 17-year experience.
    Int J Urol. 2023;30:572-578.
    PubMed     Abstract available


    June 2023
  29. KATO T, Tohi Y, Honda T, Matsuda I, et al
    A national questionnaire survey of Japanese urologists on treatment perspectives for elderly prostate cancer patients.
    Int J Urol. 2023 Jun 23. doi: 10.1111/iju.15203.
    PubMed     Abstract available


  30. SHIEKH M, Houenstein H, Ramahi YO, Shabir U, et al
    Development and validation of nomogram to improve the specificity of multiparametric MRI for clinically significant prostate cancer.
    Int J Urol. 2023 Jun 17. doi: 10.1111/iju.15225.
    PubMed     Abstract available


  31. SHOJI S
    Editorial Comment to Fusion-targeted biopsy significantly improves prostate cancer detection in biopsy-naive men.
    Int J Urol. 2023 Jun 9. doi: 10.1111/iju.15222.
    PubMed    


  32. HASHINE K, Yamashita N, Tachou T, Kan M, et al
    Radical prostatectomy trends between 2010 and 2020 in Ehime, Japan, identified using data from the Medical Investigation Cancer Network (MICAN) study.
    Int J Urol. 2023;30:547-553.
    PubMed     Abstract available


  33. SOMA T, Fukuda S, Matsuyama Y, Ikeda R, et al
    Peritoneal closure and the processus vaginalis transection method to prevent inguinal hernia after robot-assisted radical prostatectomy.
    Int J Urol. 2023;30:532-538.
    PubMed     Abstract available


    May 2023
  34. MIYAZAWA Y, Hori K, Tsuji Y, Sekine Y, et al
    The utility of the [-2]pro-prostate-specific antigen level as a prognostic marker in patients with castration-resistant prostate cancer treated with enzalutamide.
    Int J Urol. 2023 May 31. doi: 10.1111/iju.15212.
    PubMed     Abstract available


  35. TEISHIMA J
    Editorial Comment to "Fusion-targeted biopsy significantly improves prostate cancer detection in biopsy-naive men".
    Int J Urol. 2023 May 7. doi: 10.1111/iju.15202.
    PubMed    


  36. GOTO Y, Utsumi T, Maruo M, Kurozumi A, et al
    Development and validation of novel nomogram to identify the candidates for extended pelvic lymph node dissection for prostate cancer patients in the robotic era.
    Int J Urol. 2023 May 2. doi: 10.1111/iju.15195.
    PubMed     Abstract available


    April 2023
  37. BLAS L, Shiota M, Tsukahara S, Goto S, et al
    Fusion-targeted biopsy significantly improves prostate cancer detection in biopsy-naive men.
    Int J Urol. 2023 Apr 20. doi: 10.1111/iju.15188.
    PubMed     Abstract available


  38. LEE K, Shiota M, Takamatsu D, Ushijima M, et al
    Correlation between extended pelvic lymph node dissection and urinary incontinence at early phase after robot-assisted radical prostatectomy.
    Int J Urol. 2023;30:340-346.
    PubMed     Abstract available


    March 2023
  39. YOSHIDA S, Takahara T, Tanaka H, Yokoyama M, et al
    The role of prostate-specific antigen changes in predicting overall survival after progressive-site directed therapy for oligoprogressive castration-resistant prostate cancer.
    Int J Urol. 2023 Mar 31. doi: 10.1111/iju.15185.
    PubMed    


    February 2023
  40. KRAUSEWITZ P, Farzat M, Ellinger J, Ritter M, et al
    Omitting routine cystography after RARP: Analysis of complications and readmission rates in suprapubic and transurethral drained patients.
    Int J Urol. 2023;30:211-218.
    PubMed     Abstract available


  41. FURUMIDO J, Maishi N, Yanagawa-Matsuda A, Kikuchi H, et al
    Stroma biglycan expression can be a prognostic factor in prostate cancers.
    Int J Urol. 2023;30:147-154.
    PubMed     Abstract available


    January 2023
  42. KIJIMA T
    Editorial Comment to Novel quantitative software for automatically excluding red bone marrow on whole-body magnetic resonance imaging in patients with metastatic prostate cancer: A pilot study.
    Int J Urol. 2023 Jan 24. doi: 10.1111/iju.15147.
    PubMed    


  43. KISHIDA T
    Editorial Comment on a national questionnaire survey of Japanese urologists on active surveillance for low- and intermediate-risk prostate cancer.
    Int J Urol. 2023 Jan 18. doi: 10.1111/iju.15142.
    PubMed    


  44. YAMAGUCHI H, Kato T, Ishikawa Y, Takemasa K, et al
    Safety of hydrogel spacers for rectal wall protection in patients with prostate cancer: A retrospective analysis of 200 consecutive cases.
    Int J Urol. 2023 Jan 18. doi: 10.1111/iju.15140.
    PubMed     Abstract available


  45. KITAMURA K, China T, Nagata M, Isotani S, et al
    Prediction of recovery time of urinary incontinence following robot-assisted laparoscopic prostatectomy.
    Int J Urol. 2023;30:77-82.
    PubMed     Abstract available


    December 2022
  46. MATSUMOTO R
    Editorial Comment to "A national questionnaire survey of Japanese urologists on active surveillance for low- and intermediate-risk prostate cancer".
    Int J Urol. 2022 Dec 21. doi: 10.1111/iju.15127.
    PubMed    


  47. KOHADA Y, Satani N, Kaiho Y, Iwamura H, et al
    Novel quantitative software for automatically excluding red bone marrow on whole-body magnetic resonance imaging in patients with metastatic prostate cancer: A pilot study.
    Int J Urol. 2022 Dec 20. doi: 10.1111/iju.15124.
    PubMed     Abstract available


  48. OGASAWARA N, Nakiri M, Kurose H, Ueda K, et al
    Sarcopenia and excess visceral fat accumulation negatively affect early urinary function after I-125 low-dose-rate brachytherapy for localized prostate cancer.
    Int J Urol. 2022 Dec 15. doi: 10.1111/iju.15120.
    PubMed     Abstract available


  49. KADONO Y
    Editorial Comment to Predictive factors of de novo overactive bladder in clinically localized prostate cancer patients after robot-assisted radical prostatectomy.
    Int J Urol. 2022 Dec 14. doi: 10.1111/iju.15074.
    PubMed    


  50. WATANABE K, Otsuka A, Sano A, Sato R, et al
    Predictive factors of de novo overactive bladder in clinically localized prostate cancer patients after robot-assisted radical prostatectomy.
    Int J Urol. 2022 Dec 13. doi: 10.1111/iju.15060.
    PubMed     Abstract available


  51. NARUKAWA T, Fujihara A, Ochiai A, Okihara K, et al
    Role of hydrogel spacer to protect the rectum from thermal injury in focal therapy of prostate cancer: Preclinical study in cadaver model.
    Int J Urol. 2022 Dec 9. doi: 10.1111/iju.15062.
    PubMed    


  52. TANAKA N, Nakai Y, Asakawa I, Yamaki K, et al
    Local dose (biologically effective dose >/=180 Gy2) is an important predictor of biochemical recurrence in patients undergoing low-dose-rate brachytherapy.
    Int J Urol. 2022;29:1560-1568.
    PubMed     Abstract available


  53. OHARA E, Kawamorita N, Satake Y, Kaiho Y, et al
    Minimal residual membranous urethral length and membranous urethral length predict poor recovery from incontinence after robot-assisted radical prostatectomy and after open radical prostatectomy.
    Int J Urol. 2022;29:1517-1523.
    PubMed     Abstract available


  54. OJIMA K, Horiguchi A, Shinchi M, Tabei T, et al
    Transperineal bulbovesical anastomosis for extensive posterior urethral stenoses after treatment of prostatic disease.
    Int J Urol. 2022;29:1511-1516.
    PubMed     Abstract available


  55. WASHINO S, Ito K, Miyagawa T
    Prostate-specific antigen level, biopsy grade group, and tumor-capsular contact length on magnetic resonance imaging are independently associated with an extraprostatic extension.
    Int J Urol. 2022;29:1455-1461.
    PubMed     Abstract available


    November 2022
  56. KATO T, Tohi Y, Honda T, Matsuda I, et al
    A national questionnaire survey of Japanese urologists on active surveillance for low- and intermediate-risk prostate cancer.
    Int J Urol. 2022 Nov 22. doi: 10.1111/iju.15102.
    PubMed     Abstract available


  57. ARAI M, Kosaka T, Yasumizu Y, Takeda T, et al
    Androgen deprivation therapy duration is significantly associated with Testosterone recovery in Japanese patients with prostate cancer.
    Int J Urol. 2022 Nov 14. doi: 10.1111/iju.15098.
    PubMed     Abstract available


  58. TERADA N, Sawada A, Kawanishi H, Fujimoto T, et al
    The efficacy of sequential therapy with docetaxel and cabazitaxel for castration-resistant prostate cancer: A retrospective multi-institutional study in Japan.
    Int J Urol. 2022 Nov 14. doi: 10.1111/iju.15097.
    PubMed     Abstract available


  59. TOBU S, Noguchi M
    Long-term outcomes of Blocksom vesicostomy for elderly patients with chronic urinary retention.
    Int J Urol. 2022;29:1357-1361.
    PubMed     Abstract available


    October 2022
  60. YOSHIDA S, Takahara T, Arita Y, Toda K, et al
    Patterns of recurrence in genuine and induced oligometastatic castration-resistant prostate cancer treated with progressive site-directed therapy.
    Int J Urol. 2022 Oct 31. doi: 10.1111/iju.15090.
    PubMed     Abstract available


  61. SHIMBO M, Ohyama T, Endo F, Komatsu K, et al
    Simplified approach to the medial internal iliac region using a uretero-hypogastric nerve fascia development procedure for extended pelvic lymph node dissection during robot-assisted radical prostatectomy for high-risk prostate cancer.
    Int J Urol. 2022 Oct 28. doi: 10.1111/iju.15082.
    PubMed     Abstract available


  62. MATSUMOTO T, Hori Y, Shiota M, Blas L, et al
    Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: A multi-institutional study.
    Int J Urol. 2022 Oct 28. doi: 10.1111/iju.15078.
    PubMed     Abstract available


  63. HORI S, Nakai Y, Tachibana A, Omori C, et al
    Clinical significance of limited and extended pelvic lymph node dissection during robot-assisted radical prostatectomy for patients with localized prostate cancer: A retrospective, propensity score matching analysis.
    Int J Urol. 2022 Oct 28. doi: 10.1111/iju.15075.
    PubMed     Abstract available


  64. FUKUHARA S, Nonomura N
    Editorial Comment to Sperm cryopreservation before definitive therapy for early-stage prostate cancer: A single institution experience.
    Int J Urol. 2022 Oct 28. doi: 10.1111/iju.15079.
    PubMed    


  65. VAN EECKE H, Devos G, Vansevenant B, Vander Stichele A, et al
    Defining the optimal template of salvage lymph node dissection for unilateral pelvic nodal recurrence of prostate cancer following radical prostatectomy.
    Int J Urol. 2022 Oct 28. doi: 10.1111/iju.15066.
    PubMed     Abstract available


  66. YAMAMICHI G, Kato T, Yumiba S, Tomiyama E, et al
    Diagnostic and prognostic significance of tartrate-resistant acid phosphatase type 5b in newly diagnosed prostate cancer with bone metastasis: A real-world multi-institutional study.
    Int J Urol. 2022 Oct 28. doi: 10.1111/iju.15063.
    PubMed     Abstract available


  67. MIYOSHI Y, Kawahara T, Kuroda S, Takeshima T, et al
    Sperm cryopreservation before definitive therapy for early-stage prostate cancer: A single institution experience.
    Int J Urol. 2022 Oct 28. doi: 10.1111/iju.15047.
    PubMed    


  68. HINATA N, Yamaguchi R, Kusuhara Y, Kanayama H, et al
    Hinotori Surgical Robot System, a novel robot-assisted surgical platform: Preclinical and clinical evaluation.
    Int J Urol. 2022;29:1213-1220.
    PubMed     Abstract available


  69. ISHIKAWA H, Hiroshima Y, Kanematsu N, Inaniwa T, et al
    Carbon-ion radiotherapy for urological cancers.
    Int J Urol. 2022;29:1109-1119.
    PubMed     Abstract available


  70. TSUBOUCHI K, Gunge N, Tominaga K, Matsuzaki H, et al
    Efficacy of the opened legs position for protecting against postoperative rhabdomyolysis after robot-assisted radical prostatectomy: A propensity score-matched analysis of perioperative outcomes.
    Int J Urol. 2022;29:1132-1138.
    PubMed     Abstract available


  71. HAYASHI T, Hinata N
    Current status and future prospects of antibody-drug conjugates in urological malignancies.
    Int J Urol. 2022;29:1100-1108.
    PubMed     Abstract available


    September 2022
  72. YAMAMOTO Y, Ishii M, Yoshimura A, Hayashi T, et al
    Efficacy of cabazitaxel in patients with metastatic castration-resistant prostate cancer: A single-center study in Japan.
    Int J Urol. 2022 Sep 28. doi: 10.1111/iju.15052.
    PubMed     Abstract available


  73. GOTO Y
    Editorial Comment to miRNAs in prostate cancer: Intercellular and extracellular communications.
    Int J Urol. 2022 Sep 20. doi: 10.1111/iju.15058.
    PubMed    


  74. URABE F, Yamamoto Y, Kimura T
    miRNAs in prostate cancer: Intercellular and extracellular communications.
    Int J Urol. 2022 Sep 19. doi: 10.1111/iju.15043.
    PubMed     Abstract available


  75. YADAV S, Kumar A
    Editorial Comment by Dr Yadav and Dr Kumar to 'Impact of family history on clinicopathological variables and disease progression in Japanese prostate cancer patients undergoing robotic-assisted radical prostatectomy'.
    Int J Urol. 2022 Sep 12. doi: 10.1111/iju.15032.
    PubMed    


  76. KOSHIRO N, Nakajima K, Oyama M, Kaneko G, et al
    Predictive factors for the effectiveness of novel androgen receptor axis-targeted agents in patients with metastatic prostate cancer.
    Int J Urol. 2022 Sep 7. doi: 10.1111/iju.15022.
    PubMed     Abstract available


    August 2022
  77. SAKAMOTO S
    Editorial Comment on "Treatment strategies and outcomes in a long-term registry study of patients with high-risk metastatic hormone-naive prostate cancer in Japan: An interim analysis of the J-ROCK study".
    Int J Urol. 2022 Aug 29. doi: 10.1111/iju.15016.
    PubMed    


  78. UEMURA H, Matsumoto R, Mizokami A, Miyake H, et al
    Treatment strategies and outcomes in a long-term registry study of patients with high-risk metastatic hormone-naive prostate cancer in Japan: An interim analysis of the J-ROCK study.
    Int J Urol. 2022 Aug 26. doi: 10.1111/iju.14993.
    PubMed     Abstract available


  79. GOTO Y
    Editorial comment to Trends in primary treatment for localized prostate cancer according to the availability of treatment modalities and the impact of introducing robotic surgery.
    Int J Urol. 2022 Aug 24. doi: 10.1111/iju.15017.
    PubMed    


  80. KATO M
    Editorial comments on Patient-reported outcomes of a phase II neoadjuvant Apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial.
    Int J Urol. 2022 Aug 24. doi: 10.1111/iju.15013.
    PubMed    


  81. URABE F
    Editorial Comment from Dr. Urabe to Impact of family history on clinicopathological variables and disease progression in Japanese prostate cancer patients undergoing robotic-assisted radical prostatectomy.
    Int J Urol. 2022 Aug 24. doi: 10.1111/iju.15011.
    PubMed    


  82. YANG X, Allen JC, Aslim EJ, Tay KJ, et al
    Patient-reported outcomes of a phase II neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial.
    Int J Urol. 2022 Aug 24. doi: 10.1111/iju.14994.
    PubMed     Abstract available


  83. SASAKI T, Matsumoto R, Higashi S, Kato M, et al
    Impact of family history on clinicopathological variables and disease progression in Japanese prostate cancer patients undergoing robotic-assisted radical prostatectomy.
    Int J Urol. 2022 Aug 24. doi: 10.1111/iju.14990.
    PubMed     Abstract available


  84. FUJIHARA A, Ukimura O
    Focal therapy of localized prostate cancer.
    Int J Urol. 2022 Aug 22. doi: 10.1111/iju.14991.
    PubMed     Abstract available


  85. HORI S, Nakai Y, Tomizawa M, Morizawa Y, et al
    Trends in primary treatment for localized prostate cancer according to the availability of treatment modalities and the impact of introducing robotic surgery.
    Int J Urol. 2022 Aug 17. doi: 10.1111/iju.15003.
    PubMed     Abstract available


  86. KAWAHARA T, Miyoshi Y, Ninomiya S, Sato M, et al
    Administration of radium-223 and the prognosis in Japanese bone metastatic castration-resistant prostate cancer patients: A large database study.
    Int J Urol. 2022 Aug 17. doi: 10.1111/iju.15008.
    PubMed     Abstract available


  87. ZHANG Y, Song XL, Yu B, Foong LC, et al
    TP53 loss-of-function causes vulnerability to autophagy inhibition in aggressive prostate cancer.
    Int J Urol. 2022 Aug 17. doi: 10.1111/iju.15021.
    PubMed     Abstract available


    July 2022
  88. KIMURA K, Kitajima K, Kawanaka Y, Yokoyama H, et al
    Evaluation of (11) C-choline positron emission tomography/computed tomography for determining treatment response in castration-resistant prostate cancer patients.
    Int J Urol. 2022 Jul 25. doi: 10.1111/iju.14992.
    PubMed     Abstract available


  89. KATO T, Yokomizo A, Matsumoto R, Tohi Y, et al
    Comparison of the medical costs between active surveillance and other treatments for early prostate cancer in Japan using data from the PRIAS-JAPAN study.
    Int J Urol. 2022 Jul 19. doi: 10.1111/iju.14977.
    PubMed     Abstract available


    June 2022
  90. KASHIWAGI E, Shiota M, Naganuma H, Monji K, et al
    Testosterone level in seminal vesicle fluid is a better indicator of erectile function than serum testosterone in patients with prostate cancer.
    Int J Urol. 2022 Jun 18. doi: 10.1111/iju.14953.
    PubMed     Abstract available


  91. KONISHI T, Washino S, Okochi T, Miyagawa T, et al
    Combination of biparametric magnetic resonance imaging with prostate-specific antigen density to stratify the risk of significant prostate cancer: Initial biopsy and long-term follow-up results.
    Int J Urol. 2022 Jun 13. doi: 10.1111/iju.14948.
    PubMed     Abstract available


    May 2022
  92. NARITA S, Terada N, Nomura K, Sakamoto S, et al
    Cancer-specific and net overall survival in older patients with de novo metastatic prostate cancer initially treated with androgen deprivation therapy.
    Int J Urol. 2022 May 25. doi: 10.1111/iju.14938.
    PubMed     Abstract available


  93. BANNO T, Nakamura K, Kaneda Y, Ozaki A, et al
    Detection rate and variables associated with incidental prostate cancer by holmium laser enucleation of the prostate.
    Int J Urol. 2022 May 18. doi: 10.1111/iju.14917.
    PubMed     Abstract available


  94. SEKITO T, Sadahira T
    Editorial Comment to Detection rate and variables associated with incidental prostate cancer by holmium laser enucleation of the prostate.
    Int J Urol. 2022 May 18. doi: 10.1111/iju.14934.
    PubMed    


  95. TAVERNA G, Grizzi F, Tidu L, Bax C, et al
    Accuracy of a new electronic nose for prostate cancer diagnosis in urine samples.
    Int J Urol. 2022 May 9. doi: 10.1111/iju.14912.
    PubMed     Abstract available


    April 2022
  96. FUJITA K, Matsushita M, Banno E, De Velasco MA, et al
    Gut microbiome and prostate cancer.
    Int J Urol. 2022 Apr 6. doi: 10.1111/iju.14894.
    PubMed     Abstract available


  97. ZANG Z, Wang Z, Chiong E
    Editorial Comment to Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-c
    Int J Urol. 2022 Apr 5. doi: 10.1111/iju.14891.
    PubMed    


  98. KATO M
    Editorial Comment to Tenascin C regulates cancer cell glycolysis and tumor progression in prostate cancer.
    Int J Urol. 2022 Apr 2. doi: 10.1111/iju.14890.
    PubMed    


    March 2022
  99. KAMITANI N, Miyaji Y, Tamada T, Yoden E, et al
    Feasibility of magnetic resonance imaging-ultrasound guided high-dose-rate brachytherapy for localized prostate cancer: Preliminary results from a prospective study.
    Int J Urol. 2022 Mar 30. doi: 10.1111/iju.14880.
    PubMed     Abstract available


  100. SHIOTA M
    Editorial Comment to Effect of upfront combination therapy on the overall survival of patients with metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
    Int J Urol. 2022 Mar 16. doi: 10.1111/iju.14864.
    PubMed    


  101. UEMURA H, Arai G, Uemura H, Suzuki H, et al
    Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III
    Int J Urol. 2022 Mar 15. doi: 10.1111/iju.14843.
    PubMed     Abstract available


  102. SASAKI D, Hatakeyama S, Tanaka T, Okamoto T, et al
    Impact of body size on skin-related adverse events in advanced prostate cancer treated with apalutamide: A multicenter retrospective study.
    Int J Urol. 2022 Mar 13. doi: 10.1111/iju.14860.
    PubMed    


  103. NARITA T, Hatakeyama S, Ohyama C
    Editorial Comment to Comparative oncological outcomes after radical prostatectomy or external beam radiation therapy plus androgen deprivation therapy in men with clinical T3b prostate cancer.
    Int J Urol. 2022 Mar 1. doi: 10.1111/iju.14849.
    PubMed    


    February 2022
  104. QIAN Y, Liu X, Feng Y, Li X, et al
    Tenascin C regulates cancer cell glycolysis and tumor progression in prostate cancer.
    Int J Urol. 2022 Feb 25. doi: 10.1111/iju.14830.
    PubMed     Abstract available


  105. TAMURA K, Matsushita Y, Watanabe H, Motoyama D, et al
    Limited impact of erectile function on health-related quality of life in Japanese men undergoing robot-assisted radical prostatectomy.
    Int J Urol. 2022 Feb 17. doi: 10.1111/iju.14826.
    PubMed     Abstract available


  106. LEE W, Lim B, Kyung YS, Kim CS, et al
    Comparative oncological outcomes after radical prostatectomy or external beam radiation therapy plus androgen deprivation therapy in men with clinical T3b prostate cancer.
    Int J Urol. 2022 Feb 8. doi: 10.1111/iju.14799.
    PubMed     Abstract available


  107. TANAKA T, Hatakeyama S, Noro D, Togashi K, et al
    Effect of upfront combination therapy on the overall survival of patients with metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
    Int J Urol. 2022 Feb 7. doi: 10.1111/iju.14817.
    PubMed    


    January 2022
  108. YANG Y, Liu Z, Wang Q, Chang K, et al
    Presence of CD133-positive circulating tumor cells predicts worse progression-free survival in patients with metastatic castration-sensitive prostate cancer.
    Int J Urol. 2022 Jan 31. doi: 10.1111/iju.14801.
    PubMed     Abstract available


  109. BLAS L, Shiota M, Nagakawa S, Tsukahara S, et al
    Validation of models predicting lymph node involvement probability in patients with prostate cancer.
    Int J Urol. 2022 Jan 31. doi: 10.1111/iju.14802.
    PubMed     Abstract available


  110. NAGUMO Y, Onozawa M, Kojima T, Terada N, et al
    Efficacy of combined androgen blockade therapy in patients with metastatic hormone-sensitive prostate cancer stratified by tumor burden.
    Int J Urol. 2022 Jan 25. doi: 10.1111/iju.14793.
    PubMed     Abstract available


  111. MOROZUMI K, Mitsuzuka K, Narita S, Takahashi M, et al
    Impact of Gleason pattern 5 on prognosis for newly diagnosed metastatic hormone-sensitive prostate cancer with Gleason score >/=8.
    Int J Urol. 2022 Jan 18. doi: 10.1111/iju.14781.
    PubMed     Abstract available


  112. HASEGAWA M, Yamada K, Shigeta K, Yuzuriha S, et al
    How long should urologists observe patients with prostate cancer after radical prostatectomy? Weibull analysis.
    Int J Urol. 2022 Jan 4. doi: 10.1111/iju.14774.
    PubMed     Abstract available


  113. YAMASHITA S, Kawabata H, Deguchi R, Ueda Y, et al
    Myosteatosis as a novel predictor of urinary incontinence after robot-assisted radical prostatectomy.
    Int J Urol. 2022;29:34-40.
    PubMed     Abstract available


    December 2021
  114. TAKAHARA K, Naiki T, Ito T, Nakane K, et al
    Useful predictors of progression-free survival for Japanese patients with LATITUDE-high-risk metastatic castration-sensitive prostate cancer who received upfront abiraterone acetate.
    Int J Urol. 2021 Dec 4. doi: 10.1111/iju.14754.
    PubMed     Abstract available


    November 2021
  115. WURNSCHIMMEL C, Wenzel M, Chierigo F, Simone Flammia R, et al
    Response to Re: External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients.
    Int J Urol. 2021 Nov 17. doi: 10.1111/iju.14743.
    PubMed    


  116. OWARI T, Tanaka N, Nakai Y, Miyake M, et al
    Impact of neoadjuvant androgen deprivation therapy on postimplant prostate D90 and prostate volume after low-dose-rate brachytherapy for localized prostate cancer.
    Int J Urol. 2021 Nov 11. doi: 10.1111/iju.14738.
    PubMed     Abstract available


  117. SO WZ, Wang Z, Tiong HY
    Re: External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients.
    Int J Urol. 2021 Nov 5. doi: 10.1111/iju.14741.
    PubMed    


    October 2021
  118. YUASA T
    Editorial Comment to Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer.
    Int J Urol. 2021 Oct 6. doi: 10.1111/iju.14725.
    PubMed    


  119. AKAKURA K
    Editorial Comment to External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients.
    Int J Urol. 2021 Oct 4. doi: 10.1111/iju.14723.
    PubMed    


  120. YAMAMOTO S
    Editorial Comment to Prognostic implication of staging of seminal vesicle invasion in patients with prostatic adenocarcinoma after prostatectomy.
    Int J Urol. 2021;28:1045-1046.
    PubMed    


  121. FUKUNAGA A, Maejima A, Shinoda Y, Matsui Y, et al
    Prognostic implication of staging of seminal vesicle invasion in patients with prostatic adenocarcinoma after prostatectomy.
    Int J Urol. 2021;28:1039-1045.
    PubMed     Abstract available


  122. TEO XL, Lim SK
    Targeting the vessels first: A modified surgical technique for prostatic paraganglioma.
    Int J Urol. 2021;28:1073-1074.
    PubMed    


    September 2021
  123. WURNSCHIMMEL C, Wenzel M, Chierigo F, Flammia RS, et al
    External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients.
    Int J Urol. 2021 Sep 22. doi: 10.1111/iju.14701.
    PubMed     Abstract available


  124. SHIOTA M, Blas L, Kobayashi S, Matsumoto T, et al
    Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer.
    Int J Urol. 2021 Sep 22. doi: 10.1111/iju.14702.
    PubMed     Abstract available


  125. KADONO Y
    Editorial Comment to Comparison of disease-specific quality of life in prostate cancer patients treated with low-dose-rate brachytherapy: A randomized controlled trial of silodosin versus naftopidil.
    Int J Urol. 2021 Sep 8. doi: 10.1111/iju.14690.
    PubMed    


  126. COLARIETI A, Thiruchelvam N, Barrett T
    Evaluation of image-based prognostic parameters of post-prostatectomy urinary incontinence: A literature review.
    Int J Urol. 2021;28:890-897.
    PubMed     Abstract available


    August 2021
  127. MAESAKA F, Tanaka N, Nakai Y, Asakawa I, et al
    Comparison of disease-specific quality of life in prostate cancer patients treated with low-dose-rate brachytherapy: A randomized controlled trial of silodosin versus naftopidil.
    Int J Urol. 2021 Aug 10. doi: 10.1111/iju.14667.
    PubMed     Abstract available


  128. NAKAI Y, Tanaka N, Fujii T, Miyake M, et al
    Trends in risk classification at diagnosis and choice of primary therapy for prostate cancer: An analysis of 10 839 patients from the Nara Urological Research and Treatment Group registry between 2004 and 2015.
    Int J Urol. 2021 Aug 5. doi: 10.1111/iju.14666.
    PubMed     Abstract available


    July 2021
  129. MIYAMOTO S, Goto K, Honda Y, Terada H, et al
    Tumor contact length of prostate cancer determined by a three-dimensional method on multiparametric magnetic resonance imaging predicts extraprostatic extension and biochemical recurrence.
    Int J Urol. 2021 Jul 5. doi: 10.1111/iju.14633.
    PubMed     Abstract available


  130. SHIGEMURA K, Fujisawa M
    Prevention and management of infectious complications in prostate biopsy: A review.
    Int J Urol. 2021;28:714-719.
    PubMed     Abstract available


    June 2021
  131. SUGIHARA T
    Editorial Comment to Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups.
    Int J Urol. 2021 Jun 24. doi: 10.1111/iju.14620.
    PubMed    


  132. NAKAJIMA K, Mizokami A, Matsuyama H, Ichikawa T, et al
    Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort study.
    Int J Urol. 2021 Jun 19. doi: 10.1111/iju.14614.
    PubMed     Abstract available


  133. ANDELA CD, Matte R, Jazet IM, Zonneveld WC, et al
    Effect of androgen deprivation therapy on cognitive functioning in men with prostate cancer: A systematic review.
    Int J Urol. 2021 Jun 14. doi: 10.1111/iju.14596.
    PubMed     Abstract available


  134. KIMURA Y, Honda M, Teraoka S, Yumioka T, et al
    Impact of penile rehabilitation with phosphodiesterase-5 inhibitors on recovery of erectile function in patients undergoing robot-assisted radical prostatectomy: A propensity score-matched analysis.
    Int J Urol. 2021;28:637-642.
    PubMed     Abstract available


  135. TAGUCHI S, Morikawa T, Shibahara J, Fukuhara H, et al
    Prognostic significance of tertiary Gleason pattern in the contemporary era of Gleason grade grouping: A narrative review.
    Int J Urol. 2021;28:614-621.
    PubMed     Abstract available


    May 2021
  136. STOLZENBACH LF, Deuker M, Colla-Ruvolo C, Nocera L, et al
    Radical prostatectomy improves survival in selected metastatic prostate cancer patients: A North American population-based study.
    Int J Urol. 2021 May 28. doi: 10.1111/iju.14586.
    PubMed     Abstract available


  137. CHIKAMATSU S, Shiota M, Onozawa M, Hinotsu S, et al
    Dynamics of conditional survival and risk factors in androgen deprivation therapy for prostate cancer using a multi-institutional Japan-wide database.
    Int J Urol. 2021 May 24. doi: 10.1111/iju.14605.
    PubMed     Abstract available


  138. INOUE T, Yoshimura K, Terada N, Tsukino H, et al
    Prostate-specific antigen density during dutasteride treatment for 1 year predicts the presence of prostate cancer in benign prostatic hyperplasia after the first negative biopsy (PREDICT study).
    Int J Urol. 2021 May 18. doi: 10.1111/iju.14590.
    PubMed     Abstract available


  139. WURNSCHIMMEL C, Wenzel M, Colla Ruvolo C, Nocera L, et al
    Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups.
    Int J Urol. 2021 May 15. doi: 10.1111/iju.14595.
    PubMed     Abstract available


  140. IGUCHI T, Kimura G, Fukasawa S, Suzuki H, et al
    Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.
    Int J Urol. 2021 May 6. doi: 10.1111/iju.14568.
    PubMed     Abstract available


  141. CLAPS F, Ramirez-Backhaus M, Mir Maresma MC, Gomez-Ferrer A, et al
    Indocyanine green guidance improves the efficiency of extended pelvic lymph node dissection during laparoscopic radical prostatectomy.
    Int J Urol. 2021;28:566-572.
    PubMed     Abstract available


  142. MATTI B, Zargar-Shoshtari K
    Age-adjusted reference values for prostate-specific antigen in a multi-ethnic population.
    Int J Urol. 2021;28:578-583.
    PubMed     Abstract available


  143. LOW AW, Chen K, Tan YG, Ng TK, et al
    Ambulatory robot-assisted laparoscopic radical prostatectomy with extended recovery by total extraperitoneal approach.
    Int J Urol. 2021;28:561-565.
    PubMed     Abstract available


    April 2021
  144. YOSHIDA S, Fujii Y
    Editorial Comment to Long-term clinical outcomes of external beam radiation therapy for oligometastatic prostate cancer: A combination of prostate-targeted treatment and metastasis-directed therapy.
    Int J Urol. 2021 Apr 22. doi: 10.1111/iju.14578.
    PubMed    


  145. AIZAWA R, Takayama K, Nakamura K, Ogata T, et al
    Long-term clinical outcomes of external beam radiation therapy for oligometastatic prostate cancer: A combination of prostate-targeted treatment and metastasis-directed therapy.
    Int J Urol. 2021 Apr 2. doi: 10.1111/iju.14567.
    PubMed     Abstract available


  146. TATENUMA T, Makiyama K, Ito Y, Muraoka K, et al
    Correlation of urinary loss rate after catheter removal and long-term urinary continence after robot-assisted laparoscopic radical prostatectomy.
    Int J Urol. 2021;28:440-443.
    PubMed     Abstract available


  147. HAGA N, Miyazaki T, Tsubouchi K, Okabe Y, et al
    Comprehensive approach for preserving cavernous nerves and erectile function after radical prostatectomy in the era of robotic surgery.
    Int J Urol. 2021;28:360-368.
    PubMed     Abstract available


    February 2021
  148. KUSHWAHA B, Devi A, Maikhuri JP, Rajender S, et al
    Inflammation driven tumor-like signaling in prostatic epithelial cells by sexually transmitted Trichomonas vaginalis.
    Int J Urol. 2021;28:225-240.
    PubMed     Abstract available


    January 2021
  149. FALAGARIO UG, Lantz A, Jambor I, Martini A, et al
    Using biomarkers in patients with positive multiparametric magnetic resonance imaging: 4Kscore predicts the presence of cancer outside the index lesion.
    Int J Urol. 2021;28:47-52.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.